Stock RPTX REPARE THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Repare Therapeutics Inc.

Equities

RPTX

US7602731025

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
3.2 USD 0.00% Intraday chart for Repare Therapeutics Inc. -1.84% -56.16%
Apr. 26 Repare Therapeutics Inc. Announces Directorate Changes CI
Feb. 28 Repare Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Repare Therapeutics Inc. is a clinical-stage precision oncology company focused on the development of synthetic lethality (SL)-based therapies for patients with cancer. The Company is engaged in the proprietary SL approach to the discovery and development of novel therapeutics. It uses its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop cancer therapies focused on genomic instability, including deoxyribonucleic acid (DNA) damage repair. The Company’s initial product candidate, camonsertib (RP-3500 or RG6526), a potent and selective oral small molecule inhibitor of Ataxia-Telangiectasia and Rad3-related protein kinase (ATR) for the treatment of solid tumors with specific DNA damage repair-related genomic alterations, including those in the ataxia telangiectasia mutated kinase (ATM) gene as part of a network of 16 STEP2-identified genomic alterations. Its other pipeline includes Lunresertib PKMYT1 Inhibitor and RP-3467 polymerase theta (Pol0) Inhibitor.

Number of employees: 179

Sales per Business

USD in Million2022Weight2023Weight Delta
Precision Oncology Drugs
100.0 %
132 100.0 % 51 100.0 % -61.21%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
51.1 %
15 11.5 % 26 51.1 % +71.71%
Switzerland
28.4 %
117 88.5 % 15 28.4 % -87.56%
Japan
20.5 %
-- 11 20.5 % -

Managers

Managers TitleAgeSince
Lloyd Segal CEO
 Chief Executive Officer 60 16-05-31
Steve Forte DFI
 Director of Finance/CFO 45 19-09-30
Michael Zinda CTO
 Chief Tech/Sci/R&D Officer 53 19-04-30
Maria Koehler CTO
 Chief Tech/Sci/R&D Officer 67 19-04-30
Robin T. Garner IRC
 Investor Relations Contact - -
Daniel Bélanger HRO
 Human Resources Officer - 23-05-08
Philip Herman PRN
 Corporate Officer/Principal - 22-01-04
Kim Seth PRN
 Corporate Officer/Principal - 17-05-31

Members of the board

Members of the board TitleAgeSince
Carol Schafer BRD
 Director/Board Member 60 19-02-28
Lloyd Segal CEO
 Chief Executive Officer 60 16-05-31
Ann Rhoads BRD
 Director/Board Member 58 20-06-09
Todd Foley BRD
 Director/Board Member 52 17-05-31
David Bonita BRD
 Director/Board Member 48 19-08-31
Susan Molineaux BRD
 Director/Board Member 70 23-06-07
Briggs Morrison BRD
 Director/Board Member 65 17-05-31
Thomas Civik CHM
 Chairman 55 21-09-06
Samarth Kulkarni BRD
 Director/Board Member 45 19-10-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 42,182,177 41,737,875 ( 98.95 %) 0 98.95 %

Shareholders

NameEquities%Valuation
BVF, Inc.
24.50 %
10,333,600 24.50 % 49 M $
MPM BioImpact, Inc
9.204 %
3,882,485 9.204 % 18 M $
OrbiMed Advisors Private Equity
7.877 %
3,322,488 7.877 % 16 M $
Blue Owl Healthcare Opportunities Advisors LLC
7.402 %
3,122,499 7.402 % 15 M $
Deep Track Capital LP
7.095 %
2,992,731 7.095 % 14 M $
CHI Advisors LLC
7.033 %
2,966,674 7.033 % 14 M $
ARK Investment Management LLC
6.410 %
2,703,783 6.410 % 13 M $
Versant Venture Management LLC
6.274 %
2,646,657 6.274 % 12 M $
Redmile Group LLC
5.094 %
2,148,748 5.094 % 10 M $
Artal Group SA
1.659 %
700,000 1.659 % 3 M $

Company contact information

Repare Therapeutics, Inc.

7171 Frederick-Banting Suite 270

H4S 1Z9, Saint-Laurent

+

http://www.reparerx.com
address Repare Therapeutics Inc.(RPTX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Repare Therapeutics Inc.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
3.2 USD
Average target price
15.33 USD
Spread / Average Target
+379.17%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
REPARE THERAPEUTICS INC. Stock Repare Therapeutics Inc.
-56.16% 136M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.77% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+12.24% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+7.44% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.01% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+30.56% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.82% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+8.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. RPTX Stock
  4. Company Repare Therapeutics Inc.